UBS Maintains Buy on Kodiak Sciences, Raises Price Target to $150
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results
Kodiak Sciences to Present at Three Upcoming Investor Conferences
Kodiak Sciences (KOD) Stock Looks At A Premium On Its Huge 3 Year Run
Kodiak Sciences Files Shelf Prospectus For Offering; Size Not Disclosed
HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $126
Kodiak Sciences Inc. (KOD) Presents at American Academy of Ophthalmology Conference 2026 - Slideshow
Kodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data Update
Kodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial News
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III Study
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
Kodiak Sciences More Than Doubles on Eye Disease Trial Results
What Does Regeneron Pharmaceuticals (REGN) Need To Prove In Eye Disease Now?
Kodiak Sciences (KOD) Climbs Nearly 3x on Promising Wet AMD Trial
Why This Regeneron Eye Rival Just Catapulted More Than 120%
Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 172%
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
Kodiak skyrockets on positive study data for 2 eye drugs
Kodiak’s stock rallies on Phase III wAMD success
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.